{"id":891528,"date":"2026-09-11T08:26:12","date_gmt":"2026-09-11T08:26:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/891528\/"},"modified":"2026-09-11T08:26:12","modified_gmt":"2026-09-11T08:26:12","slug":"phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/891528\/","title":{"rendered":"Phase 3 study shows aQIVc superior to comparators in older adults"},"content":{"rendered":"

Combining three enhancement strategies into one shot sounds straightforward, but nobody had run a large-scale trial to prove the combination works better than its individual parts. Data published in The Lancet Infectious Diseases now fill that gap: a 7,699-person Phase 3 study of CSL Seqirus\u2019s MF59-adjuvanted, cell-based, higher-dose quadrivalent vaccine (aQIVc)<\/a> showed superior immunogenicity against all four influenza strains versus an adjuvanted egg-based comparator, and non-inferiority against a recombinant vaccine for three of four strains in adults 50 and older, and all four strains in those 65 and older.<\/p>\n

The three-component approach is the real clinical question here. Cell-based manufacturing has been used to improve strain match since Flucelvax\u2019s 2012 approval<\/a>; MF59 adjuvant has a long track record in older adults; and higher antigen doses have been available since Sanofi\u2019s Fluzone High-Dose was licensed in 2009<\/a>. What the Lancet study establishes is that stacking all three in a single formulation produces immune responses that held through the full influenza season, with most adverse reactions mild to moderate and resolving within three days. That persistence matters for older adults specifically, because immune senescence blunts and shortens vaccine-induced responses.<\/p>\n

The study also reported exploratory data on neuraminidase antibody responses, which were higher for aQIVc than for both comparators. Neuraminidase immunity is not yet a regulatory endpoint, and the authors frame it as warranting further evaluation rather than a proven efficacy signal, but it gives immunisation advisory groups another variable to weigh when comparing enhanced vaccine options for older populations.<\/p>\n

AUJEMFLU, the marketed name for aQIVc\u2019s trivalent formulation, has already cleared the MHRA for adults 50 and older in the UK and received European Commission approval. CSL Seqirus has filed in additional markets and plans a phased rollout tied to local regulatory and policy timelines. The immediate signal to watch is whether National Immunisation Technical Advisory Groups in those pending markets cite the Lancet data when setting their enhanced-vaccine recommendations for the 2027 season.<\/p>\n

Source link: https:\/\/www.prnewswire.com\/news-releases\/lancet-publication-marks-important-advance-in-influenza-prevention-for-older-adults-302875820.html<\/a><\/p>\n

\"\"<\/a><\/p>\n

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.<\/p>\n","protected":false},"excerpt":{"rendered":"Combining three enhancement strategies into one shot sounds straightforward, but nobody had run a large-scale trial to prove…\n","protected":false},"author":2,"featured_media":891529,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,84],"class_list":["post-891528","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/891528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=891528"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/891528\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/891529"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=891528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=891528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=891528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}